证券代码：002275 证券简称：桂林三金 桂林三金药业股份有限公司 桂林三金 2022 年度业绩说明会 投资者活动记录表 编号： 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □电话会议 □其他： （请文字说明其他活动内容） 参与单位名称 及人员姓名 桂林三金2022年度业绩说明会采用网络远程方式进行，面向全体投资 者 时间 2023 年 5 月 8 日 15:00-17:00 地点 深圳证券交易所 "互动易平台 "http://irm.cninfo.com.cn "云访谈 "栏 目 公司接待人员 姓名 主持人：桂林三金 董事长：邹洵 副总裁兼财务负责人：谢元钢 董秘：李春 独立董事：何里文 投资者关系活动 主要内容介绍 1.请问邹董事长：我注意到三金公司的一线品种在各电商平台上价格较 乱，请问公司如何管控渠道价格？ 答：您好，互联网平台有其自身特点，多以打折促销引流，实现销售 数量和用户数量的增加。我公司产品在各大电商平台均有销售，部分 产品以不同品规、剂型开展线上销售工作。谢谢！ 2.请问邹董事长：2023 年一季度业绩怎么样 医疗终 ...

Financial Performance - The company's operating revenue for the current period reached ¥715,925,262.60, representing a 38.51% increase compared to the same period last year[1] - Net profit attributable to shareholders was ¥169,225,122.04, marking a 40.96% year-over-year growth[1] - The net profit after deducting non-recurring gains and losses was ¥163,783,894.84, up 42.86% from the previous year[1] - The basic earnings per share increased to ¥0.29, reflecting a 38.10% rise compared to the same period last year[1] - The weighted average return on equity improved to 5.84%, an increase of 2.95% from the previous year[1] - Total operating revenue for Q1 2023 reached ¥715,925,262.60, a significant increase from ¥516,891,871.81 in the same period last year, representing a growth of approximately 38.5%[21] - Net profit for Q1 2023 was ¥169,225,122.04, compared to ¥120,053,789.34 in the previous year, reflecting an increase of approximately 40.9%[24] - The total comprehensive income for the period was CNY 167,284,723.54, compared to CNY 119,558,821.49 in the previous period, representing an increase of approximately 39.9%[26] - Basic and diluted earnings per share increased to CNY 0.29 from CNY 0.21, reflecting a growth of 38.1%[26] Assets and Liabilities - Total assets at the end of the period were ¥4,121,500,711.51, a 3.95% increase from the end of the previous year[1] - The company's total assets increased to ¥4,121,500,711.51 from ¥3,964,926,749.15, marking a growth of about 3.9%[20] - Total liabilities decreased slightly to ¥1,129,072,575.33 from ¥1,151,594,802.44, a reduction of approximately 1.9%[20] - The total equity attributable to shareholders increased to ¥2,992,428,136.18 from ¥2,813,331,946.71, representing a growth of about 6.4%[20] Cash Flow - The company's cash flow from operating activities decreased by 67.67% to ¥54,238,486.87 compared to the same period last year[1] - Cash inflows from operating activities totaled CNY 706,984,153.47, up from CNY 638,327,757.79, indicating an increase of about 10.5%[27] - Cash outflows from operating activities amounted to CNY 652,745,666.60, compared to CNY 470,559,776.83 in the previous period, which is an increase of approximately 38.6%[27] - Net cash flow from operating activities was CNY 54,238,486.87, down from CNY 167,767,980.96, a decrease of about 67.6%[27] - Net cash flow from investing activities was CNY -68,739,822.89, slightly improved from CNY -73,360,724.97 in the previous period[30] - Net cash flow from financing activities increased significantly to CNY 115,975,857.88 from CNY 12,206,733.48, representing a growth of approximately 855.5%[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,948, with the largest shareholder holding 62.07% of shares[9] - The top ten shareholders include both individual and institutional investors, with the largest shareholder being Guilin Sanjin Group[9] - The first phase of the employee stock ownership plan has a total of 6,147,975 shares unlocked, accounting for 1.05% of the total share capital[13] Government Subsidies - The company received government subsidies amounting to ¥7,910,246.54 during the current period[2] - The company received a government subsidy of 49 million RMB for a technology renovation project, expected to increase annual profit by 39.2 million RMB[13] Accounts Receivable and Inventory - Accounts receivable increased by 91.54% to ¥138,225,323.30, primarily due to increased sales and annual credit granted to distributors[4] - Accounts receivable increased to approximately 138.23 million RMB from 72.17 million RMB year-to-date[14] - The company’s inventory decreased to approximately 229.43 million RMB from 244.90 million RMB at the beginning of the year[14] Borrowings - Short-term borrowings rose by 102.77% to ¥283,900,256.67, mainly due to the renewal of loans that were due in the previous period[4] - The company’s long-term borrowings rose to ¥216,109,646.76 from ¥128,029,669.26, an increase of approximately 68.8%[20] Research and Development - Research and development expenses for the quarter were ¥73,161,443.46, compared to ¥70,056,723.81, showing an increase of about 3.0%[21]

Financial Performance - The company's total revenue for 2022 was ¥1,959,732,845.90, representing a 12.55% increase from ¥1,741,224,552.65 in 2021[22] - Net profit attributable to shareholders for 2022 was ¥329,526,519.63, a decrease of 4.13% compared to ¥343,718,942.74 in 2021[22] - The net profit after deducting non-recurring gains and losses was ¥222,383,595.89, down 14.62% from ¥260,467,690.06 in the previous year[22] - Basic earnings per share for 2022 was ¥0.56, a decrease of 6.67% compared to ¥0.60 in 2021[22] - Total assets at the end of 2022 were ¥3,964,926,749.15, down 3.20% from ¥4,095,868,127.50 at the end of 2021[22] - Net assets attributable to shareholders decreased by 0.93% to ¥2,813,331,946.71 from ¥2,839,817,165.26 in 2021[22] - Cash flow from operating activities increased by 28.87% to ¥528,666,938.97 from ¥410,241,541.70 in 2021[22] Product Development and Innovation - The company reported a total of 217 drug approvals, including 47 unique specialty products and 69 products listed in the National Essential Medicines List, indicating a strong product portfolio[47] - The company has 73 valid invention patents, including 1 US patent, showcasing its commitment to innovation and research[47] - The company completed 4 new drug projects and received 3 IND approvals for its biopharmaceutical pipeline, marking a significant step in its innovation journey[134] - The company is currently conducting Phase I clinical trials for a humanized anti-PD-L1 monoclonal antibody injection, aiming to enrich its biological drug pipeline[164] - The company has successfully launched new products and enhanced existing ones, focusing on both independent innovation and the development of traditional Chinese medicine[132] Market Position and Brand Value - The company has maintained a strong market position, being ranked among the top 50 Chinese traditional medicine companies and the top 100 pharmaceutical manufacturers in China[60] - The brand value of "SanJin" is estimated at CNY 11.229 billion, ranking it 4th in the pharmaceutical industry according to the World Brand Lab[60] - The market share of the "Guangxi Watermelon Frost" product in the oral ulcer traditional Chinese medicine market is 46.78%, while "SanJin Pian" holds a 43% market share in the urinary tract infection segment[121] - The company has received significant recognition for its products, including awards from the Guangxi Science and Technology Progress Award and inclusion in national guidelines for treating ischemic stroke[92] Strategic Goals and Future Outlook - The company aims to be a leading pharmaceutical manufacturing group in China, focusing on traditional Chinese medicine and biotechnology, with a strategy that emphasizes both core and auxiliary industries[46] - The Chinese pharmaceutical market is expected to grow significantly due to increasing health awareness and an aging population, providing a favorable outlook for the company's future[59] - The company aims to enhance its market presence through innovative product development and strategic partnerships in the healthcare sector[78] - The demand for traditional Chinese medicine products is expected to expand due to the aging population and increasing chronic disease rates, presenting new market opportunities[99] Risk Management - The company has identified risks including industry policy changes, product price declines, and increased market competition[13] - The company faces risks related to fluctuations in raw material prices, which could impact profitability[101] - The establishment of a national procurement office for traditional Chinese medicine may pose price reduction risks for the company's products[113] Operational Efficiency - The company has a comprehensive quality management system that has been recognized with multiple awards, including the National Quality Award nomination in 2018[125] - The company has a robust distribution network with 60 main distributors and 995 secondary distributors, ensuring effective market coverage[125] - The company has established an independent financial accounting department, ensuring compliance with national accounting laws and regulations[103] Research and Development - R&D investment as a percentage of operating revenue was 11.07%, down from 11.63%, a decrease of 0.56%[166] - The number of R&D personnel decreased to 253, a decline of 1.94% from 258 in the previous year[166] - R&D expenses rose by 7.20% to ¥217,036,372.78 compared to ¥202,449,905.05 in the previous year[182] Sales and Marketing - The pharmaceutical segment contributed CNY 1,856,101,015.73, accounting for 94.71% of total revenue, with a year-on-year growth of 12.28%[136] - The revenue from direct sales increased by 36.44% year-on-year, primarily due to growth in the Shanghai R&D and CDMO business[157] - The company's inventory for traditional Chinese medicine decreased by 39.35% year-on-year, driven by significant sales growth of key products[157]

桂林三金药业股份有限公司（以下简称"公司"）《2022年年度报告》已于 2023年4月26日经公司第八届董事会第二次会议审议通过，详情见2023年4月28 日《中国证券报》《上海证券报》《证券时报》《证券日报》和巨潮资讯网 （http://www.cninfo.com.cn）。为使广大投资者更加全面、深入地了解公司情 况，公司将于2023年5月8日召开2022年度业绩说明会，具体如下： 一、业绩说明会相关安排 1、时间：2023年5月8日（星期一）15:00-17:00。 2、召开方式：本次年度业绩说明会将采用网络远程文字交流的方式举行。 证券代码：002275 证券简称：桂林三金 公告编号：2023-016 桂林三金药业股份有限公司 关于召开2022年度业绩说明会并征集问题的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 欢迎广大投资者积极参与本次网上业绩说明会。 特此公告。 3 、 参 与 方 式 ： 投 资 者 可 通 过 深 圳 证 券 交 易 所 "互动 易 " 平 台 （http://irm.cninfo.com.cn）进入"云访谈"栏目参与 ...

Group 1: Company Overview and Strategic Goals - Guilin Sanjin aims to modernize traditional Chinese medicine through innovation, focusing on modern Chinese medicine preparations as its core industry [2] - The company plans to expand its vertical industry chain and explore fields such as biopharmaceuticals, chemical drugs, and health products to enhance its professional management level [3] Group 2: Health Industry Development - After integrating Guilin Sanjin Watermelon Frost Ecological Company into its listing system, the company will focus on research and development in the health sector, leveraging its market and brand advantages in throat-related traditional Chinese medicine [3] - The company intends to develop oral care products like Watermelon Frost toothpaste to extend its product line and optimize its business structure [3] Group 3: Biopharmaceuticals and Future Plans - Baoshuan Biotech, established in 2005, specializes in the research and production of biopharmaceuticals, with several biosimilar drugs under development targeting malignant tumors [4] - The company aims to submit 1-2 products for clinical trials within the year [4] Group 4: Expansion and Acquisition Strategy - To maintain its leading position in the traditional Chinese medicine industry, Guilin Sanjin is actively seeking strategic acquisitions of quality domestic pharmaceutical companies [4] - The company plans to capitalize on the upcoming deadline for new GMP certification to acquire pharmaceutical enterprises with strong product and resource advantages [4]

附件二、投资者关系活动记录表 证券代码： 002275 证券简称：桂林三金 桂林三金药业股份有限公司投资者关系活动记录表 编号：2015006 | --- | --- | --- | |-------------------------|----------------------------------|--------------------------------------------------------| | | | | | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | □ 一对一沟通 | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | | 建信基金管理公司 邵卓 陶灿 孙晟 吴尚伟 | | | | | | 时间 | 2015 年 06 月 19 日 | | | 地点 | 桂林三金药业股份有限公司 | | | 上市公司接待人 | 董事常务副总裁兼董事会秘书：邹洵 | | | 员 | 投资者关系管理专员： ...